Ken Griffin Relay Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,500 shares of RLAY stock, worth $6,510. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,500
Previous 1,700
11.76%
Holding current value
$6,510
Previous $11,000
9.09%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding RLAY
# of Institutions
204Shares Held
156MCall Options Held
207KPut Options Held
40K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$121 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$62.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$45.8 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.25MShares$40.1 Million5.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.38MShares$32 Million0.88% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $522M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...